Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics (STOK) reported Phase III EMPEROR enrollment completion of 162 patients and said a Phase III readout is expected in Q3 2027. Rolling NDA submissions are planned for Q1 2027, with a potential early 2028 launch of zorevunersen. Q2 revenue was $9.3M and net loss $61.6M. Pro forma cash was about $420M.
How this was made
The 30-second read
Why it matters
The disclosed milestones (Phase III enrollment completion, week-28 endpoint population, rolling NDA initiation timing, and early 2028 launch plan) plus a stated pro forma cash balance and runway can shift near-to-medium term valuation by changing perceived probability-weighted outcomes.
Market read
Traders can update models for STOK based on the updated regulatory and launch timeline, the week-28 endpoint population milestone, and the cash runway into a potential U.S. commercial launch.
What to watch
The call emphasizes operational milestones and cash runway, but traders may underweight the risk that FDA feedback on the rolling NDA sequence and SAP could delay submission modules or require additional analyses.
Background
This is a transcript-style summary of Stoke Therapeutics’ Q2 2026 business and financial update, centered on zorevunersen Phase III progress and pipeline expansion.
Ticker impact
Stoke reported Phase III EMPEROR enrollment completion (162 patients) and set rolling NDA start in Q1 2027, with commercial launch targeted for early 2028.
Likely positive bias for STOK on expectations of improved execution and funding visibility, though volatility remains around future efficacy and FDA interactions.
The call provides multiple concrete, decision-relevant milestones (enrollment, endpoint timing, rolling NDA modules, cash position and runway) rather than generic commentary.
Market effects
Reinforces investor appetite for late-stage antisense and rare-disease neurology programs with credible rolling NDA pathways and long-term OLE evidence.
Limited direct regional spillover; primarily affects U.S. rare-disease biotech sentiment and clinical-stage risk appetite.
Moderate, as the EMPEROR program spans the U.S., U.K., and Japan, but the disclosed decision points are U.S.-centric (rolling NDA, launch timing).
Counterpoint
Enrollment completion and retention metrics do not guarantee efficacy at the week-28 primary endpoint; the market may discount timelines if effect size or p-value targets are not ultimately met.
Key entities
- companyStoke Therapeutics, Inc.
STOK, advancing zorevunersen through Phase III EMPEROR and planning rolling NDA modules starting Q1 2027.
- drug_programzorevunersen
Lead antisense therapy in the Phase III EMPEROR study for Dravet syndrome.
- clinical_trialEMPEROR study
Phase III trial with enrollment completion reported at 162 patients and primary endpoint measurement at week 28.
- drug_programSTK-002 (OSPREY study)
Phase I program with dose escalation underway and initial safety/efficacy readout targeted for H1 2027.
- drug_programSYNGAP1 program
Multiple candidates in lead optimization with a goal to select a clinical development candidate in 2027.
